Beyond the Hype: Pragmatic Solutions for Advancing Psychedelic Therapeutics
Adrian Preda
Psychiatric News April 19, 2024 DOI: 10.1176/appi.pn.2024.05.5.25 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Keywords | Epistemology Psychotherapist Cognitive science |
| Key points | Argues that psychedelic clinical trials are especially vulnerable to socio-cultural influences and therefore require unusually rigorous design—randomization, blinding, and stronger controls than standard psychotropic trials—to prevent false positive findings that could harm the field. |
Abstract
In my editorial in the previous issue of Psychiatric News, I discussed the risk of socio-cultural factors affecting the integrity of psychedelic clinical trials (PCTs). In light of these substances' cultural significance, history, and powerful effects (including observable changes in consciousness), rigorous clinical trial design—with randomization, blinding, and control requirements above those typical of nonpsychedelic psychotropic clinical trials—is required. A high level of stringency for psychedelic clinical trials is a necessary safeguard against false positive outcomes that could, in turn, hurt this rapidly expanding area of research.